CAPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Capricor Therapeutics Inc (CAPR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is supported by strong analyst upgrades, positive clinical trial results, and potential FDA approval for its flagship therapy, Deramiocel. Despite short-term technical weakness and financial challenges, the long-term growth prospects and significant upside potential make it a compelling investment.
The technical indicators show mixed signals. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negatively expanding (-0.164), and RSI is neutral at 40.898. The stock is trading near its support level of 25.607, with resistance at 28.892, suggesting limited immediate upside but potential for recovery.
Strong Phase III HOPE-3 trial results for Deramiocel, showing significant efficacy in treating Duchenne muscular dystrophy.
Analyst upgrades with increased price targets (e.g., $50, $45, and $
and high confidence in FDA approval by mid-
Upcoming presentation of clinical trial results at the Muscular Dystrophy Association conference, which could drive investor interest.
Financial challenges, including a 100% YoY revenue drop and continued negative net income (-$24.57M in Q3 2025).
FDA's request for additional clinical data, which may delay approval timelines.
Year-to-date stock price decline of 12%, reflecting cautious investor sentiment.
The company's financials for Q3 2025 show a revenue drop to $0 (-100% YoY), but net income improved to -$24.57M (+95.68% YoY), and EPS increased to -0.54 (+42.11% YoY). Despite no revenue, the company is managing costs effectively, which may support its operations until FDA approval.
Analysts are highly bullish on CAPR, with multiple upgrades and price target increases (e.g., $50, $45, $54). They cite strong clinical data, a high probability of FDA approval, and significant revenue potential by 2030 ($1.1B in risk-adjusted net sales).
